文献速递肺外科心外重症与机械循环支持

无血肺移植:两种VA-ECMO抗凝策略对肺移植结局的影响比较

Bloodless lung transplantation: Comparison between 2 central venoarterial extracorporeal membrane oxygenation anticoagulation strategies and their impact on lung transplant outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-10-10

该回顾性研究比较肺移植术中VA-ECMO两种抗凝方案对结局的影响。低剂量肝素组手术时间更短且血制品用量显著减少,但3级原发性移植物功能障碍等术后结局无差异。

要点

  • 低剂量肝素VA-ECMO方案显著减少术中血制品使用
  • 低剂量肝素组手术时间更短(7.28 vs 8.53小时)
  • 两组严重3级原发性移植物功能障碍发生率无差异

核心结论

  • 低剂量肝素VA-ECMO方案显著减少肺移植术中血制品使用,且术后结局相似。

主要发现

  • 低剂量肝素组手术时间7.28小时 vs 标准组8.53小时(P < .001)。
  • 低剂量肝素组术中红细胞中位数0 vs 4.37单位(P < .001),新鲜冰冻血浆中位数0 vs 2单位(P < .001),血小板中位数0 vs 1单位(P < .001),冷沉淀中位数0 vs 0单位(P < .001),总血制品中位数0 vs 9单位(P < .001)。
  • 两组深静脉血栓(P = .13)、气道裂开(P > .99)、肺炎(P = .38)、需肾脏替代治疗的急性肾损伤(P = .59)发生率无差异。
  • 移植后72小时严重3级原发性移植物功能障碍发生率无差异(P = .42)。

关键数值与推荐

  • 低剂量肝素方案:插管时给予75单位/千克肝素,不再追加,ECMO启动后输注氨甲环酸。
  • 标准方案:维持目标活化凝血时间>180秒,拔管后鱼精蛋白逆转。

临床怎么用

  • 肺移植术中VA-ECMO采用低剂量肝素联合氨甲环酸方案可减少血制品输注,且不增加术后不良结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report differences between 2 anticoagulation protocols during venoarterial extracorporeal membrane oxygenation (VA-ECMO) intraoperative support and their effects on outcomes after lung transplantation. METHODS: We performed a retrospective analysis of patients undergoing double-lung transplantation with intraoperative VA-ECMO from January 1, 2016, to December 30, 2023. Two distinct anticoagulation protocols were in place during this period. One included targeted activated clotting time >180 seconds at all times with protamine reversal after decannulation. The second included 75 units per kilogram of heparin at the time of cannulation with no redosing plus a tranexamic acid infusion after ECMO initiation. RESULTS: A total of 116 patients (46 low heparin, 70 standard) were included in the analysis. Cannulation strategies and ECMO circuit were equivalent between the groups. The low-dose heparin protocol group had a shorter surgical time (7.28 hours vs 8.53 hours, P < .001) and required significantly less intraoperative packed red blood cells (median 0 vs 4.37 units, P < .001), fresh-frozen plasma (median 0 vs 2 units, P < .001), platelets (median 0 vs 1 units, P < .001), cryoprecipitate (median 0 vs 0 units, P < .001), and total blood products (median 0 vs 9 units, P < .001) compared with the standard group. There were no differences in rates of deep vein thrombosis (P = .13), airway dehiscence (P > .99), pneumonia (P = .38), or acute kidney injury requiring renal-replacement therapy (P = .59). There was no difference in rates of severe grade 3 primary graft dysfunction at 72 hours after transplant (P = .42). CONCLUSIONS: Our low-dose heparin VA-ECMO protocol for intraoperative support during lung transplantation led to a significant reduction of blood product use. Although this did not translate to a reduced rates of grade 3 primary graft dysfunction, the low-dose heparin protocol was associated with similar postoperative outcomes.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chan EG, Deitz RL, Ryan JP, et al. Bloodless lung transplantation: Comparison between 2 central venoarterial extracorporeal membrane oxygenation anticoagulation strategies and their impact on lung transplant outcomes. J Thorac Cardiovasc Surg. 2024. PMID: 39393627. doi:10.1016/j.jtcvs.2024.09.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。